个人简历
1982年：苏州医学院本科毕业 1982-1993年：苏州医学院附属第一医院神经外科 神经外科硕士（1989），神经外科博士（1993）1993-1996年：加拿大McGill 大学神经外科博士后 1996-1999年：加拿大McGill 大学神经外科/肿瘤科Research associate 1999年11月-：中山大学肿瘤防治中心神经外科/神经肿瘤科主任
研究领域
从事神经外科医疗、教学和科研工作三十余年，在神经外科疾病的诊断和治疗方面拥有丰富的经验。对脑（神经系统）肿瘤的显微外科手术和综合治疗具有较深的造诣，特别是脑胶质瘤的个体化综合治疗，采用包括依据肿瘤分子特征的预见性化疗、CIK细胞局部免疫治疗等使数以千计的病人获得良好的治疗效果。除了高超的临床医术之外，陈忠平教授还在基础研究方面颇有建树。在神经肿瘤分子生物学-尤其是胶质瘤耐药/放射抗拒分子机制方面做了较深入的研究,在恶性脑肿瘤免疫治疗的基础和临床应用方面也进行了探索。首先提出并用转基因试验证明，核苷酸切除修复系统中的重要因子 - ERCC2的表达与人脑肿瘤对烷化剂的耐药相关；实验和临床研究证明DNA修复基因六氧甲基鸟嘌呤DNA甲基转移酶基因(MGMT)表达影响人脑胶质瘤对氯乙基亚硝脲化疗的效果，抑制MGMT活性可为化疗增敏。
近期论文
1.Chen ZP,Malapetsa A,Marcantonio D,Mohr G,Brien S,Panasci LC.Correlation of chloroethylnitrosourea resistance with ERCC-2 expression in human tumor cell lines as determined by quantitative competitive polymerase chain reaction. Cancer Research ,1996,56: 2475-2478. 2.Chen ZP,Mohr G,Panasci LC.Correlation between GST-μgene expression and chloroethylnitrosourea resistance in human brain tumor cell lines. Acta Academicae Medicinae Suzhou,1996,2:59-64. 3.Chen ZP,Malapetsa A,Brien S,Mohr G,Panasci LC.Quantitation of ERCC-2 expression by reverse-transcription polymerase chain reaction comparison to Northern blot analysis. Anal Biochem,1997,244: 50-54. 4.Chen ZP,Malapetsa A,McQuillan A,Marcantonia D,Bello V,Mohr G,Remack J,Brent TP,Panasci LC.Evidence for nucleotide excision repair as a modifying factor of MGMT mediated innate chloroethylnitrosourea resistance in human tumor cell lines. Molecular Pharmacology,1997,52: 815-820. 5.Chen ZP,Yarosh D,Garcia Y,Tampieri D,Mohr G,Langleben A,Panasci LC.Clinical response of O6-methylguanine-DNA methyltransferase levels to 1,3-(2-chloroethyl)-1-nitrosourea chemotherapy in glioma patients.Neurosurgical Focus,1998,4(6):artical 3. 6.Chen ZP,McQuillan A,Mohr G,Panasci LC.Excision repair cross-complementing rodent repair dificiency gene2 expression and chloroethylnitrosourea resistance in human glioma cell lines. Neurosurgery,1998,42(5)1112-1119. 7.Chen ZP,Remack J,Brent TP,Mohr G,Panasci LC.Extraneuronal Monoamine Transporter Expression vis-à-vis SauCNU Cytotoxicity in Human Tumor Cell Lines.Clinical Cancer Research, 1999,5:4186-4190. 8.Chen ZP,Wang G,Huang Q,Sun ZF,Zhou LY,Wang AD,Panasci LC.Enhanced antitumor activity of SarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive human glioma xenograft model. J Neuro-Oncology,1999,44:7-14. 9.Chen ZP,Pan J,Huang Q,Sun ZF,Zhou LY,Wang AD.Antitumor efficacy of SarCNU in a Human Glioma Xenograft Model expressing both MGMT and Extraneuronal Monoamine Transporter.J Neuro-Oncology,2001,51:19-24. 10.Chen ZP,Carter CA,Alley MC,Mohr G,Panasci LC.Both Extraneuronal Monoamine Transporter and O6-methylguanine-DNA Methyltransferase Expression Influence the Antitumor Efficacy of SarCNU in Human Tumor Xenografts.J Pharmacol Exp Ther,2001,296(3):712-715. 11.Wang ZM,Chen ZP,Xu ZY,Christodoulopoulos G,Bello V,Mohr G,Aloyz R,Panasci LC.In vitro evidence for homologous recombinational repair in resistance to melphalan.J Natl Cancer Inst,2001,93(19):1473-1478. 12.Pan LX,Chen ZP,Liu YS,Zhao JH.Magnetic Resonance Imaging and Biological Markers in Pituitary Adenomas with Invasion of the Cavernous Sinus Space.J Neuro-oncology,2005, 74(1):71-76. 13.Yue WY,Chen ZP.Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem.2005, 53(8):997-1002. 14.Chen HY,Shao CJ,Shi HL,Mu YG,Sai K,Chen ZP.Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 vis-à-vis chemotherapy drug cytotoxicity in human gliomas.J Neuro-oncology,2007,82:257-262. 15.Shao CJ,Fu J,Shi HL,Mu YG,Chen ZP.Activities of DNA-PK and Ku86, but not Ku70, may predictsensitivity to cisplatin in human gliomas.J Neurooncol,2008,89(1):27-35. 16.Yue WY,Yu SH, Zhao SG,Chen ZP. Molecular markers relating to malignant progression in grade II astrocytoma. J Neurosurgery,2009,110(4):709-14. 17.Fu J, Liu ZG, Liu XM, Chen FR, Shi HL, Pang JC, Ng HK, Chen ZP,Glioblastoma stem cells resistant to temozolomide-induceautophagy.chinese medical journal,2009,122(11):1255-1259. 18.Fu J,Shao CJ,Chen FR,NG HK,Chen ZP.Autophagy Induced by Valproic Acid is Associated with Oxidative Stress in Glioma Cell Lines.Neuro-oncology,2010,12(4):328-340. 19.Chen HY,Shao CJ,Chen FR,Kwan AL,Chen ZP.Role of ERCC1 Promoter Hypermethylation in drug resistance to cisplatin in human gliomas. Int J Cancer,2010,126(8):1255-1259.
